| 產(chǎn)品描述： | Xevinapant (AT-406) is a potent and orally bioavailable Smac mimetic and an antagonist of IAPs, and it binds to XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM, respectively. |
| 靶點： |
cIAP1:1.9 nM (Ki);cIAP2:5.1 nM (Ki);XIAP:66.4 nM (Ki);IAP |
| 體內(nèi)研究： |
Xevinapant (AT-406) is very effective in inhibition of tumor growth in the MDA-MB-231 xenograft model, and has minimal toxicity to animals.Xevinapant is evaluated for its pharmacokinetic (PK) properties in mice, rats, non-human primates and dogs. |
| 參考文獻： |
1. Cai Q, Sun H, Peng Y, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011;54(8):2714-2726. |
| 溶解性： |
DMSO : 100 mg/mL (178.03 mM; Need ultrasonic) |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.78 ml |
8.901 ml |
17.803 ml |
| 5 mM |
0.356 ml |
1.78 ml |
3.561 ml |
| 10 mM |
0.178 ml |
0.89 ml |
1.78 ml |
| 50 mM |
0.036 ml |
0.178 ml |
0.356 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京